-
03:31:12 AM

DBTX Stock News

01/24/23 7:00 AM
Nasdaq : DBTX
clinical triallow float
Decibel Therapeutics Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Lead Gene Therapy Candidate DB-OTO
The CTA authorization for DB-OTO provides approval for the Company to expand its planned Phase 1/2 clinical trial to the U.K. in patients two years of age and younger One-time administration of DB-OTO has resulted in production of otoferlin protein and durable auditory brainstem responses to sound
RHEA-AI
neutral
10/17/22 7:00 AM
Nasdaq : DBTX
low float
Decibel Therapeutics Receives FDA Clearance of IND Application for DB-OTO, a Gene Therapy Product Candidate Designed to Provide Hearing to Individuals with Otoferlin-Related Hearing Loss
The IND for DB-OTO provides clearance for the Company to initiate a pediatric Phase 1/2 clinical trial in the U.S. in children and infants, and is part of an international regulatory strategy for clinical development One-time administration of DB-OTO has resulted in production of otoferlin protein
RHEA-AI
neutral
06/28/22 7:00 AM
Nasdaq : DBTX
clinical triallow float
Decibel Therapeutics Reports Positive Data from Interim Analysis of Ongoing Phase 1b Clinical Trial of DB-020 in Patients Receiving Cisplatin Chemotherapy
- 87% of patients who experienced ototoxicity in their placebo-treated ear were protected from ototoxicity in their DB-020-treated ear – - Data support continued development of DB-020 as a potential therapy to protect against hearing loss in patients receiving cisplatin chemotherapy for cancer – -
RHEA-AI
neutral